

SOHO France

Hematology Congress

September 24-26, 2025

La Grande Crypte
69 bis Rue Boissière
75 016 PARIS



SCIENTIFIC COMMITTEE

President of the Scientific Committee

Mauricette MICHALLET (Hematology, Centre Léon Bérard, Lyon)

Members of the Scientific Committee

- Amine BELHABRI (Hematology, Centre Léon Bérard, Lyon)
- Sylvain CHOQUET (Hematology, Hôpital Pitié-Salpêtrière, Paris)
- Roch HOUOT (Hematology, CHU de Rennes, Rennes)
- Jean-Jacques KILADJIAN (Hematology, Hôpital Saint-Louis, Paris)
- Xavier LELEU (Hematology, CHU de Poitiers, Poitiers)
- François-Xavier MAHON (Hematology, Institut Bergonié, Bordeaux)
- Anne-Sophie MICHALLET (Hematology, Centre Léon Bérard, Lyon)
- Sophie PARK (Hematology, CHU Grenoble Alpes, Grenoble)
- Christian RECHER (Hematology, Institut Universitaire du Cancer de Toulouse)
- Philippe ROUSSELOT (Hematology, Centre Hospitalier de Versailles, Le Chesnay)

WITH THE INSTITUTIONAL SUPPORT OF OUR PLATINUM PARTNERS



IDEOGEN



NOVARTIS

WITH THE INSTITUTIONAL SUPPORT OF OUR PARTNERS



BeiGene



Bristol Myers Squibb®



Daiichi-Sankyo

Johnson
& Johnson

Lilly
A MEDICINE COMPANY

ipomed
SERVICES TO HEALTH



MENARINI
group Stemline

A Menarini Group Company



Pierre Fabre

sanofi

SERVIER



Le site de l'hématologie
hemato.net

WEDNESDAY 24th SEPTEMBER 2025

08:30 - 09:00 a.m.....Opening

09:00 - 09:30 a.m.....Introduction

Mauricette MICHALLET (President of the Scientific Committee), (Hematology, Lyon)
Jean SIBILIA (Rheumatology, Strasbourg)

09:30 - 10:50 a.m.....Session 1: MYELODYSPLASTIC SYNDROMES

Chair: Sophie PARK (Hematology, Grenoble)

The practical application of IPSS-M in our everyday practice
Lin-Pierre ZHAO (Hematology, Paris)

20 min.

Treatment guidelines for low-risk MDS
Mathieu MEUNIER (Hematology, Grenoble)

20 min.

Pre-emptive or non-emptive treatment of high-risk post-allograft MDS
Thomas CLUZEAU (Hematology, Nice)

20 min.

Discussion

20 min.

10:50 - 11:05 a.m.....COFFEE BREAK & MEET OUR PARTNERS 

11:05 a.m - 12:05 p.m....THERAPEUTIC CHALLENGES IN PERIPHERAL T-CELL LYMPHOMA



12:05 - 01:05 p.m.....LUNCH BREAK

01:05 - 02:45 p.mSession 2: ACUTE MYELOID LEUKEMIA

Chairs: Arnaud PIGNEUX (Hematology, Bordeaux) & Christian RECHER (Hematology, Toulouse)

Targeting BMP and TAZ/TEAD mechanotransduction pathways alters resistance to AML therapies
Sylvain LEFORT (Hematology, Lyon)

20 min.

State of Art in the Management of AML in 2025
Hagop KANTARJIAN (Oncology Hematology, Houston (USA))

20 min.

Role of IA in Diagnostics
Torsten HAFERLACH (Oncology Hematology, Munich (Germany))

20 min.

Significance of plasma metal concentrations in patients with AML
Charles DUMONTET (Hematology, Lyon)

20 min.

Discussion

20 min.

02:45 - 04:05 p.m.....Session 3: CELL THERAPY AND TRANSPLANTATION

Chair: Anne HUYNH (SFGM-TC president) (Hematology and transplantation, Toulouse)

Managing chronic GVHD in 2025
Léonardo MAGRO (Hematology, Lille)

20 min.

Impact of donor type on transplantation outcome
Raynier DEVILLIER (Hematology, Marseille)

20 min.

Current challenges in the conditioning regimens
Maud D'AVENI-PINEY (Hematology, Nancy)

20 min.

Discussion

20 min.

04:05 - 04:20 p.m.....COFFEE BREAK & MEET OUR PARTNERS 

04:20 - 05:20 p.m.....2nd SYMPOSIUM

THURSDAY 25th SEPTEMBER 2025

08:30 - 09:00 a.mOpening

09:00 - 10:40 a.mSession 4: ACUTE LYMPHOBLASTIC LEUKEMIA

Chair: **Philippe ROUSSELOT** (Hematology, Le Chesnay)

What's new in pediatric ALL-B?

20 min.

Marion STRULLU (Paediatric Immuno-Hematology, Paris)

Results of the GRAALL 2014 protocol

20 min.

Françoise HUGUET (Hematology, Toulouse)

Management of relapsed adult Ph+ ALL

20 min.

Adrien DE VOEGHT (Hematology, Liège (Belgique))

Ferroptosis in ALL-T

20 min.

Guillaume ANDRIEU (Researcher, Paris)

Discussion

20 min.

10:40 - 10:50 a.mCOFFEE BREAK & MEET OUR PARTNERS 

10:50 a.m - 12:10 p.m....Session 5: LYMPHOMAS

Chair: **Sylvain CHOQUET** (Hematology, Paris)

NHL T/NK

20 min.

Amira MAROUF (Hematology, Paris)

NHL in patients living with HIV

20 min.

Lionel GALICIER (Internal medicine, Marseille)

Testicular NHL

20 min.

Agathe VELY (Oncology Hematology, Paris)

Discussion

20 min.

12:10 - 12:30 p.mORAL ABSTRACT

12:30 - 01:30 p.mLUNCH BREAK & POSTER WALK

01:30 - 02:30 p.mMULTIPLE MYELOMA IN FIRST RELAPSE: FOCUS ON NEW THERAPEUTIC OPTIONS

Chair: **Alexis TALBOT** (Immunology Hematology, Paris)

GSK

From standard to targeted: Decoding the European guidelines –

What is the optimal treatment in first relapse?

Thomas Chalopin (Hematology, Tours)

Treatment options at first relapse of multiple myeloma:

From theory to practice through 3 clinical scenarios

Benjamin Hebraud (Hematology, Toulouse)

Ocular toxicities of antibody-drug conjugates in hemato-oncology:
separating facts and myths

Marie Caroline Trône (Ophthalmology, Saint-Etienne)

Summary, perspectives (development plan), and Q&A

Alexis TALBOT (Immunology Hematology, Paris)

02:30- 04:00 p.m.....	Session 6: MULTIPLE MYELOMA Chair: Xavier LELEU (Hematology, Poitiers)	
	MRD immune Ludovic MARTINET (Oncogenomics and immunology, Toulouse)	15 min.
	Monoclonal gammopathy, a continuum from MGUS to MM, when to treat and for what goals and efforts Salomon MANIER (Hematology, Lille)	15 min.
	First-line therapy: quadruplet for whom and when? Arthur BOBIN (Hematology, Poitiers)	15 min.
	First line of treatment, which could be "transplant deferred" and for which autograft remains the gold standard Claudio CERCHIONE (Hematology, Meldola (Italy))	15 min.
	CAR-T or Bispecific in Multiple Myeloma, which will be the most "treatment paradigm shift"? Alexis TALBOT (Immunology Hematology, Paris)	15 min.
	Discussion	15 min.

04:00 - 04:15 p.m..... **COFFEE BREAK & MEET OUR PARTNERS** 

04:15 - 04:25 p.m..... **SHORT TALK : NEUTROPENIA ASSOCIATED WITH NEW ANTICANCER AGENTS**
Chair: Gabriel ANThERIEU (Hematology, Oullins-Pierre-Benite)



04:25 - 06:00 p.m.....	Session 7: CAR-T CELLS Chair: Marion ALCANTARA (Hematology, Saint-Cloud)	
	Predictive factors of toxicity after CAR-T cell therapy Rémy DULERY (Hematology, Paris)	20 min.
	Lessons learned after 6 years of RWE from the DESCAR-T Registry Gabriel BRISOU (Oncology Hematology, Marseille)	20 min.
	In vivo generation of CARs: how does it work? Els VERHOEYEN (Infectiology, Nice)	20 min.
	Cellular therapies (CARs, TCRs, TILs) for solid tumors: a reality? Amaury LERUSTE (Pediatrics, Paris)	20 min.
	Discussion	20 min.

FRIDAY 26th SEPTEMBER 2025

08:30 - 09:00 a.m..... **Opening**

09:00 - 10:30 a.m.....	Session 8: MYELOPROLIFERATIVE NEOPLASMS Chair: Mauricette MICHALLET (Hematology, Lyon)	
	Latest developments in the diagnosis and treatment of eosinophilia Andreas REITER (Oncology Hematology, Mannheim (Germany))	20 min.
	MPN: are young patients different ? Yan BEAUVERD (Hematology, Genève (Switzerland))	20 min.
	Molecular complexity of MPNs: diagnostic and prognostic role Nabih MASLAH (Biological hematology, Paris)	20 min.
	Discussion	20 min.

10:30 - 10:50 a.m.....ORAL ABSTRACT

10:50 - 11:50 a.m.....ON THE ROAD TO PHILADELPHIA: NEW PERSPECTIVES IN CML AND MF

Chair: Mathieu WEMEAU (Hematology, Lille)



Introduction

Management of myelofibrosis in 2025: news and perspectives

Mathieu WÉMEAU (Hematology, Lille)

CML in 1st line: What innovations & prospects?

Valérie COITEUX (Hematology, Lille)

Discussion

11:50 am - 12:00 p.m.....BREAK - DISTRIBUTION OF LUNCH BOXES

12:00 - 01:00 p.m.....5th SYMPOSIUM



01:00 - 01:15 p.m.....COFFEE BREAK & MEET OUR PARTNERS 

01:15 - 02:35 p.m.....Session 9: CHRONIC LYMPHOCYTIC LEUKEMIA

Chair: Anne-Sophie MICHALLET (Hematology, Lyon)

Shared medical decision

Therese AURRAN (Hematology, Marseille) & Julia TINLAND (Philosophy, Marseille)

20 min.

RESIST data and a new approach to the management of doubly-exposed and doubly-refractory patients

Loïc YSEBAERT (Hematology, Toulouse)

20 min.

Recommendations for managing WM

Damien ROOS WEIL (Hematology, Paris)

20 min.

Discussion

20 min.

02:35 - 02:45 p.mAWARD CEREMONY - CALL FOR ABSTRACT

02:45 - 03:00 p.m.....COFFEE BREAK & MEET OUR PARTNERS 

03:00 - 04:20 p.m.....Session 10: CHRONIC MYELOID LEUKEMIA

Chair: François-Xavier MAHON (Hematology, Bordeaux)

For whom, when and how to Use Allosteric Inhibitors in CML?

Delphine RÉA (Hematology, Paris)

20 min.

Genomic analysis in CML: are we ready for clinical practice?

Ivan SLOMA (Oncology Hematology, Créteil)

20 min.

Is the Ultimate Goal in CML Really TFR? Where Are We?

François-Xavier MAHON (Hematology, Bordeaux)

20 min.

Discussion

20 min.

04:20 - 04:30 p.m.....CLOSING REMARKS